Cyclophosphamide induces an early wave of acrolein-independent apoptosis in the urothelium

Francis M. Hughes1*, Alexa G. Corn1, Andrew R. Nimmich1, Jeffery D. Pratt-Thomas1, J. Todd Purves1,2,3

1Department of Urology, Medical University of South Carolina, Charleston, USA
2Department of Pediatrics, Medical University of South Carolina, Charleston, USA
3Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, USA

Email: *mhughes@musc.edu

Received 1 June 2013; revised 1 July 2013; accepted 16 July 2013

Copyright © 2013 Francis M. Hughes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Hemorrhagic cystitis (HC) affects a significant number of patients undergoing cyclophosphamide (CP) chemotherapy despite treatment with 2-mercaptoethane sulfonate (Mesna) to inactivate the metabolite acrolein. While the mechanism is unknown, there is clearly acrolein-independent damage to the urothelium. In this study we have explored the induction of apoptosis in the urothelium as a marker of damage and the mechanism underlying the acrolein-independent apoptosis. Two waves of apoptosis (measured as caspase-3/7 activity and Poly (ADP-ribosyl) polymerase (PARP) cleavage) were detected following CP administration, one peaking at 2 h and a second at 48 h. The first wave was not blocked by Mesna, indicating it was independent of acrolein. Caspase-1 was also active at 2 h and activation of caspase-3/7 was blocked by a caspase-1 inhibitor, but not an IL-1 receptor antagonist, suggesting the direct activation of caspase-3/7 by caspase-1 without the need for IL-1 as an intermediate. Our results indicate that CP initiates an early, acrolein-independent wave of apoptosis that results from direct cleavage of caspase-3/7 by caspase-1.

Keywords: Cystitis; Cyclophosphamide; Apoptosis; Bladder; Urothelium

1. INTRODUCTION

Cyclophosphamide (CP) is a widely used chemotherapeutic agent that causes acute hemorrhagic cystitis (HC) [1]. A metabolite of CP, acrolein, is largely responsible, leading oncologists to concomitantly administer 2-mercaptoethane sulfonate (Mesna), an orally-available drug that masks acrolein’s toxic effect. The use of Mesna has dramatically reduced, but not eliminated, HC [1-7] following CP chemotherapy. The mechanism for HC in the presence of Mesna has not been defined but clearly involves damage to the urothelium. A typical cellular response to damage is to initiate apoptosis in order to clear the damaged cell from the population. In this study, we have examined CP-induced damage to the urothelium in vivo using two independent markers of apoptosis: the activation of caspase(s)-3/7 and the cleavage of Poly (ADP-ribose) polymerase (PARP). Caspase-3/7 is considered an effector caspase and is activated in most models of apoptosis where it is directly involved in dismantling the cell by cleavage of structural and functional proteins. PARP is a DNA repair enzyme that is cleaved and inactivated ostensibly to conserve energy by not repairing DNA intentionally destroyed during the death process.

Recent studies have shown that damage to a cell or tissues is recognized by pattern recognition receptors which result in the activation of the inflammatory caspase, caspase-1 [8,9]. We have further examined the involvement of caspase-1 in the response to CP and the mechanism of its involvement.

2. MATERIALS AND METHODS

2.1. Animals

Adult female randomly cycling Sprague Dawley rats (175 - 199 g; Harlan, Pratville AL, USA) were used in all studies. All experimental protocols were approved by the Institutional Animal Care and Use Committee at our institution.

2.2. Pharmacological Treatments

Animals were injected (i.p.) with 80 mg/kg CP or saline.
We have previously shown that this dose induces changes in physiological bladder function indicative of HC within 24 h [10]. Following established protocols [11,12] the Mesna animals received Mesna at -0.5, 4 and 8 h relative to CP injection (Figure 1(a)). For caspase-1 inhibitor experiments Ac-Tyr-Val-Ala-Asp-2,6-dimethylbenzoyloxymethyl ketone (YVAD-AOM; EMD Chemicals, Rockland, MA, USA) was dissolved in DMSO (5 mg/ml), diluted in saline (to 200 µM), and 200 µl (or 200 µl of 2.5% DMSO) was instilled transurethrally in anesthetized rats (ketamine/xylazine; 90 mg/kg and 10 mg/kg i.p., respectively). Catheters were capped and left indwelling. 1 h later rats were injected i.p. with 80 mg/kg CP. One half hour later additional ketamine/xylazine (45 mg/kg, 5 mg/kg, respectively) was administered (i.p.). Two hours after CP injection rats were sacrificed. For anakinra experiments, rats were injected i.p. with 100 mg/kg anakinra (Amgen, Thousand Oaks, CA, USA) in saline (or saline alone) 1 h prior to injection of CP.

2.3. Caspase Assays
Urothelium were obtained by scraping, similar to what has been reported elsewhere [13,14]. Briefly, the isolated bladder was cut open from sphincter to dome. The dome ends were pinned and the sphincter held by forceps with a bent tip. The urothelium was gently scraped from the detrusor using a size 11 scalpel blade, twisting the blade to lift the cells. The cells were placed in ice-cold PBS, pelleted (800 × g, 10 min), resuspended in 25 µl of 10 mM MgCl₂, 0.25% Igepal CA-630, mixed with an equal volume of 40 mM Hepes (pH 7.4), 20 mM NaCl, 2 mM EDTA, 20% Glycerol and stored at -20°C until analyzed (<1 week).

Caspase-3/7 activity was measured using the Caspase Glo system from Promega Inc. (Madison, WI, USA) and the manufacturer’s recommendations. Caspase-1 was analyzed similar to our previous studies [15]. Extracts (20 µl) were combined with 50 µl assay buffer (25 mM HEPES, 5% sucrose, 0.05% CHAPS (pH 7.5)), 10 µl 100 mM dithiothreitol and 20 µl 1 mM substrate (N-Acetyl-Tyr-Val-Ala-Asp-7-amino-4-trifluoromethylcoumarin (Ac-YVAD-AFC); Enzo Life Sciences, Inc., Farmingdale, NY, USA) in blacked-walled 96 well plates. Fluorescence (Excitation 400 nm, Emission 505 nm) was measured every 30 sec for 15 min and the slope determined. A standard curve of AFC was used to calculate specific activity.

2.4. Analysis of Cleaved PARP
Cells were resuspended in 1% paraformaldehyde and incubated in turn with 200 µl of BD Bioscience’s (San Jose, CA) FACS Permeabilization Solution-2 (10 min), 1 ml of 0.5% BSA in PBS (30 min), 100 µl of anti-PARP (cleaved p85) rabbit monoclonal antibody (Epitomics, Burlingame, CA, USA; 1:50 dilution; 30 min) and 200 µl Alexa Fluor 488 conjugated goat anti-rabbit IgG (H + L); Invitrogen (Life Technologies, Carlsbad, CA, USA; 1:500 dilution, 30 min), with washing in between before being analyzed by flow cytometry.

2.5. Statistics
To test for differences over time (Figure 2), we modeled the log of percent difference from baseline (time = 0) using linear regression with fixed effects for hours from baseline, treated as categorical variables. Regression model assumptions were evaluated using residual plots and QQ-plots. p-values represent tests that percent changes from baseline were different from 0, and p values < 0.05 were considered significant. Other comparisons were conducted using non-parametric Wilcoxon rank sum tests or Student’s t-test, as appropriate, and were also considered significant if p < 0.05.
3. RESULTS

3.1. There Are Two Waves of Apoptosis Following CP Administration

Caspase-3/7 activity in urothelium was followed for 72 h after the injection of 80 mg/kg CP. As shown in Figure 2(a), we detected a biphasic induction of apoptosis with an initial peak at 2 h, followed by a return to baseline at 8 h. At 16 h, levels had increased again and continued to go up until at least the 48 h time point. While we have previously shown that this dosing paradigm induces changes in physiological bladder function indicative of HC at 24 h [10], the peak at 2 h is novel and is not associated with gross morphological change (data not shown). To confirm the 2 h result, we have examined expression of an independent apoptotic marker, cleaved PARP [16]. As shown in Figures 2(b) and (c), there was a 21.2% increase in the percentage of the urothelium cells with cleaved PARP at 2 h (% of cells under the M1 gate).

3.2. The First Wave of Caspase-3/7 Activity Is Independent of Acrolein

To access the contribution of acrolein to the two waves of apoptosis, rats were pretreated with Mesna 0.5 h prior to CP administration. Due to the short half-life of Mesna [17], rats assessed at 24 h also received additional doses of Mesna at 4 and 8 h [11,12] (Figure 1(a)). As shown in Figure 1(b), Mesna significantly (p < 0.05) reduced the caspase-3/7 activity in urothelium at 24 h but only slightly and non-significantly reduced the activity at 2 h, indicating that the early peak of apoptosis is mostly acrolein-independent while the latter wave is largely dependent on this metabolite.

3.3. A Caspase-1 Inhibitor, But Not an IL-1 Receptor Antagonist, Blocks Activation of Caspase-3/7 at 2 h

Damage to a cell or tissue often results in the activation of caspase-1. As shown in Figure 3(a), we detect significant activation of caspase-1 two hours after CP administration, further indicating urothelium damage at this time point. Working upstream, caspase-1 can cleave caspase-3/7 directly [18,19] or stimulate apoptosis through production of IL-1β [20,21]. Direct luminal instillation of the caspase-1 inhibitor YVAD-AOM blocked the increase in caspase-3/7 activity stimulated by CP after 2 h (Figure 3(b)). Caspase-3/7 activity was significantly (p < 0.05) stimulated by CP in rats that were not pretreated with anakinra (an IL-1 receptor antagonist) and in ones that were pretreated (Figure 3(c)). In addition, there was no significant (p = 0.28) difference noted between the anakinra pretreated and saline rats which did not receive CP, and there was no significant (p = 0.10) difference noted between the anakinra pretreated and saline rats which did receive CP. In other words, pretreatment of rats with the IL-1β receptor antagonist anakinra had no effect (Figure 3(c)).
4. DISCUSSION

CP-induced damage to the urothelium is clearly involved in the induction of HC. While the metabolite acrolein is largely responsible for this, the persistence of significant levels of this malady in the presence of Mesna suggests additional damage must occur. Since damage to cells often activates apoptosis, we examined the increase of this death process as an indicator of damage in response to CP. In these studies we have used a smaller dose of CP than is often used with rodents [22,23] but one we have previously documented to induce changes in physiological bladder function indicative of HC by 24 h [10]. Moreover, this dose was chosen from our institution’s protocols for treating patients with acute lymphocytic leukemia.

Using caspase-3/7 activity as a measurement of apoptosis, we detected a biphasic response with waves peaking at 2 and 48 h. The peak at 2 hours is novel and the results show a central role for pattern recognition receptors and the activation of caspase-1 [8,9]. Indeed, we detected caspase-1 activated at 2 h following CP treatment, providing further evidence of tissue damage at this time. This result also suggested two possible links between activation of this inflammatory caspase and the downstream effector caspase; caspase-3/7. Caspase-1 can directly cleave caspase-3/7 [18,19] or activate IL-1β, which itself may induce apoptosis and result in the activation of caspase-3/7 [20,21]. To differentiate between these possibilities we used a caspase-3/7 inhibitor (YVAD-AOM) and a IL-1 receptor antagonist (anakinra). While the caspase-1 inhibitor blocks the activation of caspase-3/7, anakinra had no effect which argues strongly for the direct activation of caspase-3/7 without IL-1β as an intermediate. While IL-1β is most certainly produced in our model, it is not implicated in the initial wave of apoptosis at 2 h.

Our results demonstrate that a single dose of CP at clinically relevant levels [10] can initiate an early wave of damage in the urothelium resulting in the activation of caspase-1 and apoptosis. How these events could precipitate later HC is unknown. Interestingly, recent work with herpes virus demonstrates that apoptosis can reactivate this virus [25,26]. Considering that reactivation of BK virus (latently present in 90% of adults) has been strongly implicated in the pathology underlying HC in Mesna-approved.
treated patients [3,27,28], it is tempting to speculate that apoptotic-induced viral reactivation may be involved.

Our results indicate that CP initiates an early, acrolein-independent wave of apoptosis that results from direct cleavage of caspase-3/7 by caspase-1.

5. ACKNOWLEDGEMENTS

The authors would like to thank Dr. Elizabeth Garrett-Mayer and Dr. Paul J. Nietert for their expert assistance with statistical analysis of our data. The project described was supported by Award Number UL1RR-029882 and UL1TR000062 from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health.

REFERENCES


